knowledge -WSS

knowledge

author：knowledge 2025-10-01 21:40:40 - browse：49

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare Advantage coverage denials need scrutiny, senators say

focus

leisure time

Wikipedia

WSS

Why Novartis is changing the name of its research labs

The 10 drugs up first for Medicare price negotiation

STAT Virtual Event: JPM Recap, Live!

Ethical issues complicate the benefits of medical crowdfunding

Ethical issues complicate the benefits of medical crowdfunding

Crinetics acromegaly drug succeeds in late

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA early review: GLP

Activists slam private health insurers over coverage restrictions

Illumina names Agilent executive as new CEO

Jerome Adams on the need for new antivirals for Covid

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

Arena BioWorks launches in Cambridge to speed drug discovery

Peter Hotez and the public health issue of online harassment

'Make People Better': The CRISPR babies story you probably don't know

hotspot

Profiling embryos to choose those with higher IQs is almost a reality

Gene therapy denied for Afghan refugee whose father aided U.S.

Ethical issues complicate the benefits of medical crowdfunding

Illumina names Agilent executive as new CEO

A new House health package & hospitals’ new site

Allen Institute goes after foundational questions, CEO Costa says

focus

leisure time

Wikipedia

explore